Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
21-40 of 1,307 trials

Marstacimab for Pediatric Hemophilia

We are studying a new treatment for children with severe hemophilia A or B to see if it is safer and more effective than standard care. This trial includes participants with or without inhibitors.

Haemophilia1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematology

MOG Antibody Disease: Azathioprine Study

We are testing whether azathioprine can help prevent relapses in adults with MOG antibody-associated disease after their first attack. The study also looks at safety and quality of life for participants.

Anti-Myelin-Associated Glycoprotein Antibodies Positive>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteInternal MedicineNeurology

Advanced Breast Cancer: ARV-471 vs Fulvestrant

We are studying a new medication, ARV-471, to see if it works better than fulvestrant for patients with advanced estrogen receptor-positive, HER2-negative breast cancer. This trial is for those whose cancer has progressed after prior treatments.

Advanced Breast CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

BOTOX for Masseter Muscle Prominence

We are studying whether BOTOX injections can help reduce the prominence of the masseter muscle in adults. This trial compares BOTOX to a placebo to evaluate its effectiveness and safety.

Masseter Muscle Prominence1-2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesCost ReimbursementDermatology

Prostate Cancer: Lutetium-177 vs. Standard Treatments

We are comparing a new treatment called Lutetium-177 with standard medications for men with metastatic hormone-sensitive prostate cancer. The goal is to see which option better delays disease progression and improves survival.

Prostate Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteOncologyUrology

Tranexamic Acid for Spontaneous Brain Bleeding

We are studying whether tranexamic acid can help reduce early deaths in patients with spontaneous intracerebral hemorrhage. Additionally, we will look at its effects on recovery six months later.

Stroke3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesNeurology

Systemic Lupus Erythematosus: Deucravacitinib Study

We are evaluating a new medication, deucravacitinib, for individuals with active systemic lupus erythematosus. The study aims to determine if it is more effective than a placebo in reducing disease symptoms and improving overall health.

Active Systemic Lupus Erythematosus1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementRheumatology

IgG4-Related Disease: Obexelimab Treatment Study

We are studying a new medication, obexelimab, for people with IgG4-related disease to see if it helps prevent flare-ups after steroid treatment. We will also check how safe and well-tolerated it is for patients.

IgG4-Related Disease1-2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInfectious DiseasesRheumatology

Salivary Duct Carcinoma: Dutasteride with Combined Androgen Blockade

We are studying whether adding dutasteride to standard therapy helps patients with recurrent or metastatic salivary duct carcinoma. The trial also looks at safety and quality of life for those receiving this new treatment.

Salivary Duct CarcinomaEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Hematologic Cancers: Continued Treatment with Tafasitamab

We are providing ongoing treatment for patients with blood cancers who have previously received Tafasitamab. This study focuses on evaluating the safety of continued use of this medication.

Hematological MalignancyConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Acute Myeloid Leukemia: New Treatments for Children and Adolescents

We are exploring different therapies for children and adolescents with acute myeloid leukemia to see if they improve survival and treatment outcomes. This includes testing new drugs alongside standard chemotherapy.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyPediatrics

Advanced Non-Small Cell Lung Cancer: Datopotamab Deruxtecan and Pembrolizumab

We are studying a new treatment combination for patients with advanced non-small cell lung cancer who have not had prior therapy. The goal is to see if this combination works better than standard treatments in improving survival and reducing disease progression.

Advanced Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Arrhythmic Mitral Valve Prolapse: Flecainide and Metoprolol Study

We are studying whether adding flecainide to metoprolol can better reduce irregular heartbeats in patients with arrhythmic mitral valve prolapse. This trial aims to assess the safety and effectiveness of this combination treatment.

Mitral Valve Prolapse>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Atrial Fibrillation: Colchicine Study

We are investigating whether colchicine can help prevent the return of atrial fibrillation in patients scheduled for heart rhythm treatment. We will also look at its effects on heart health and quality of life.

Atrial Fibrillation and Atrial Flutter>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesCardiology

ERASE PH-COPD: New Treatment for COPD

We are exploring a new approach for individuals with chronic obstructive pulmonary disease (COPD). The goal is to see if this treatment can improve breathing and overall health.

Pulmonary Hypertension6-12 monthsConfirmation phase (III)Pulmonology

Aspirin for Preventing Preeclampsia in First-Time Pregnant Women

We are studying whether daily aspirin can help prevent preeclampsia and improve pregnancy outcomes in women who are pregnant for the first time after assisted reproductive technology. This trial compares aspirin to a placebo to see which is more effective.

Preeclampsia>2 yearsConfirmation phase (III)Monitoring phase (IV)≤5 visitsStandard MedicinesPartially RemoteGynecology and Obstetrics

Esophageal Cancer Treatment: The NEEDS Trial

We are comparing two treatment methods for operable esophageal squamous cell carcinoma to see which may help patients survive longer. The study also examines quality of life and other health impacts during and after treatment.

Locally Advanced Esophageal Squamous Cell Carcinoma≤3 monthsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteOncology

Melanoma Treatment: Nivolumab + Relatlimab Injection Study

We are comparing a new way to give a combination treatment for advanced melanoma to see if it works as well as the traditional method. This study is for people who have not yet been treated for their melanoma.

Metastatic MelanomaConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementDermatologyOncology

Acute Venous Thromboembolism: Anticoagulant Therapy Study

We are studying whether full-dose anticoagulant therapy alone is safer and more effective than combining it with antiplatelet therapy for patients with acute VTE. This research aims to improve treatment options for those already taking antiplatelets.

Deep Venous Thrombosis and Pulmonary Embolism>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

Cirrhosis and Ascites: Personalized Human Albumin Treatment

We are studying a tailored approach to human albumin therapy for patients with liver cirrhosis and fluid buildup. The goal is to identify who may respond best to this treatment.

Liver Cirrhosis>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesCost ReimbursementHepatologyInternal Medicine